Trials / Recruiting
RecruitingNCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanzalintinib | Administered as specified in the treatment arm. |
| DRUG | Everolimus | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2025-07-21
- Primary completion
- 2029-06-01
- Completion
- 2029-06-01
- First posted
- 2025-04-24
- Last updated
- 2026-04-17
Locations
80 sites across 13 countries: United States, Australia, Austria, Canada, China, Germany, Hong Kong, Italy, Poland, Puerto Rico, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06943755. Inclusion in this directory is not an endorsement.